Immunic, Inc. (NASDAQ: IMUX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Immunic to Participate in Investor and Scientific Conferences in February
Immunic, Inc. (NASDAQ: IMUX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Immunic, Inc. (NASDAQ: IMUX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $17.00 price target on the stock.
Immunic Highlights 2024 Accomplishments and Upcoming Milestones [Yahoo! Finance]